Patent application number | Description | Published |
20080210635 | Process and system for removal of contaminants from industrial streams - A method and system for removing from an aqueous system which is contaminated therewith: (1) mercury present as colloids, ions and/or organically bound compounds, and (2) hydrocarbons solubilized, dispersed, and/or emulsified in the said system. Pursuant to the invention the aqueous system to be treated (such as “produced water”) is passed successively through three filtration stages. The first filtration stage is provided with absorption media which effects reduction/removal of dispersed organically bound mercury species and of the dispersed and partially dissolved hydrocarbon phases, as well as of some colloidal mercury and other dissolved metallic species. The second filtration stage utilizes a salt modified reticulated granular filtration media for reduction/removal of slightly dissolved hydrocarbon phases, mercury in colloidal and ionic form and other dissolved metals. The third filtration stage is a polishing stage, which serves to further reduce by electroless or voltaic reduction residual elemental mercury and/or residual colloidal and ionic mercury. At this third stage metallic mercury is incorporated into a metallic matrix from which the mercury may preferably be recovered. | 09-04-2008 |
20090139918 | Visual bilgewater quality indicator - A visual bilgewater quality indicator for use in a bilgewater filtration system which includes a filtration stage for removing oily contaminants. The quality indicator utilizes one or more filtration status chambers which are provided with a fluorescent or phosphorescent dye or pigment treated filtration media. The status chamber has a transparent outer wall. Flow through the status chamber is from the outer lateral wall toward its central axis, whereby oily contaminants in the flow collect selectively at the outer portions of the filtration media which are highly visible to an observer. Oil droplets as small as one micron, are captured and immobilized by the primary filter and are instantly visible against the background of the exemplary dye. If two status chambers are used in series, due to the ability of the infused media to permanently capture oil without re-entrainment, the second chamber is always kept transparent until complete loading and supersaturating breakthrough at the primary chamber. Oily droplet visibility can be further enhanced with ultraviolet illumination. | 06-04-2009 |
20100000409 | Process and system for separating finely aerosolized elemental mercury from gaseous streams - A method and apparatus for practicing the method are provided for separating droplets of finely aerosolized elemental mercury from a gaseous stream in which the droplets are dispersed. In the method a gold plated metallic capillary surface is contacted with the gaseous stream, causing the aerosolized droplets to deposit on the capillary surface and by capillary action to coalesce with other of such droplets to form increasingly large drops of mercury. The surface is oriented to allow the mercury to flow by gravitational forces and capillary action to the lowermost portions of the surface, at which it accumulates, and is then collected at a suitable vessel. | 01-07-2010 |
20110198276 | SYSTEM FOR REMOVAL OF CONTAMINANTS FROM INDUSTRIAL STREAMS - A method and system for removing from an aqueous system which is contaminated therewith: (1) mercury present as colloids, ions and/or organically bound compounds, and (2) hydrocarbons solubilized, dispersed, and/or emulsified in the said system. Pursuant to the invention the aqueous system to be treated (such as “produced water”)is passed successively through three filtration stages. The first filtration stage is provided with absorption media which effects reduction/removal of dispersed organically bound mercury species and of the dispersed and partially dissolved hydrocarbon phases, as well as of some colloidal mercury and other dissolved metallic species. The second filtration stage utilizes a salt modified reticulated granular filtration media for reduction/removal of slightly dissolved hydrocarbon phases, mercury in colloidal and ionic form and other dissolved metals. The third filtration stage is a polishing stage, which serves to further reduce by electroless or voltaic reduction residual elemental mercury and/or residual colloidal and ionic mercury. At this third stage metallic mercury is incorporated into a metallic matrix from which the mercury may preferably be recovered. | 08-18-2011 |
20120184039 | METHOD AND SYSTEM FOR ANALYZING CONCENTRATIONS OF DIVERSE MERCURY SPECIES PRESENT IN A FLUID MEDIUM - A method for facilitating removal of mercury from a primary fluid stream of interest which is contaminated with organically-bound, elemental, and ionic mercury species. The stream is analyzed to establish the relative content of the organically-bound, elemental, and ionic mercury species present therein by forming a diverted side stream from the primary stream, and passing the side stream successively through three in series filter stages, the first captures organically bound mercury, the second captures elemental mercury, and the third captures ionic mercury. The side stream flow through the filter stages is continued for a predetermined period, and upon conclusion of the period the quantity of mercury collected at each of the filtration stages is determined. This data is then utilized to determine the capacity of the three different filtration stages required to reduce the mercury content in the mam stream to a desired level. | 07-19-2012 |
20120273401 | VISUAL BILGEWATER QUALITY INDICATOR - A visual bilgewater quality indicator for use in a bilgewater filtration system which includes a filtration stage for removing oily contaminants. The quality indicator utilizes one or more filtration status chambers which are provided with a fluorescent or phosphorescent dye or pigment treated filtration media. The status chamber has a transparent outer wall. Flow through the status chamber is from the outer lateral wall toward its central axis, whereby oily contaminants in the flow collect selectively at the outer portions of the filtration media which are highly visible to an observer. Oil droplets as small as one micron, are captured and immobilized by the primary filter and are instantly visible against the background of the exemplary dye. If two status chambers are used in series, the second chamber is always kept transparent until complete loading and supersaturating breakthrough at the primary chamber. | 11-01-2012 |
20120315240 | VISCOELASTIC ANTIMICROBIAL COMPOSITIONS AND METHODS - Viscoelastic compositions capable of preventing microbial proliferation and capable of capturing microbrial membrane and cell wall decomposition products are provided, the compositions including reaction products of drying oils and semi-drying oils and methacrylate polymers. The compositions are capable of absorption or incorporation of lipopolysaccharide and protein membrane materials and endotoxins. | 12-13-2012 |
20120316251 | PROCESS FOR PRODUCING COMPOSITIONS FOR USE IN REMOVAL OF DISPERSED, SOLUBILIZED, AND/OR EMULSIFIED UNDESIRED SPECIES FROM WATER AND GASES - Disclosed is a method of making coagulant and viscoelastic compositions for use in removal of dispersed, solubilized, and emulsified oils and hydrocarbons and other noxious species from water and air. The composition comprises thermal reaction products of blends of fatty acids derived, isolated and purified from drying and semi-drying oils such as linseed, safflower, and tung oil with a polymer such as for example poly(isobutyl methacrylate) and can include a solvent. The product of the invention facilitates cohesion of oils and hydrocarbons independent of agitation and temperature and may be used in both salt and fresh water, air and other gaseous streams. | 12-13-2012 |
20130167719 | Visual Quality Indicator for Gaseous Streams - A visual indicator device and method for determining the presence of oily contaminants in a gaseous stream are provided. The device includes a filtration status chamber for receiving and discharging the gaseous stream, and a transparent wall enabling viewing of the chamber interior. A fluid-pervious filtration media within the chamber is infused with an absorption composition at which the contaminant on contact with the media is immobilized. The media has a surface viewable through a transparent wall of the filtration status chamber, and the stream flow path is such as to cause the stream to impinge at the media via the said surface, whereby the contaminants collect selectively at the media surface and are therefore highly visible through the transparent wall. | 07-04-2013 |
20130175000 | Visual Quality Indicator for Aqueous Streams - A visual indicator device and method for determining the presence of oily contaminants in an aqueous stream are provided. The device includes a filtration status chamber for receiving and discharging the aqueous stream, and a transparent wall enabling viewing of the chamber interior. A fluid-pervious filtration media within the chamber is infused with an absorption composition at which the contaminant on contact with the media is immobilized. The media has a surface viewable through a transparent wall of the filtration status chamber, and the stream flow path causes the stream to impinge at the media via the surface, whereby the contaminants collect selectively at the media surface and are highly visible through the transparent wall. | 07-11-2013 |
20140373715 | PROCESS AND SYSTEM FOR SEPARATING FINELY AEROSOLIZED ELEMENTAL MERCURY FROM GASEOUS STREAMS - A method and apparatus are provided for separating droplets of finely aerosolized elemental mercury from a fluid stream in which the droplets are dispersed, particularly a gaseous stream. In the method, a precious metal wire capillary surface or precious metal-coated wire capillary surface is contacted with the gaseous stream, causing the aerosolized droplets to deposit on the capillary surface and by capillary action to coalesce with other of such droplets. The surface is oriented to allow the mercury to flow by gravitational forces and capillary action to the lowermost portions of the surface, where it accumulates and can be collected. Metallic capillary surfaces comprised of finely braided strands of silver, gold, palladium, platinum, or rhodium wire, or wire coated with one or more of these metals, are particularly preferred. | 12-25-2014 |
20150305330 | ADVANCED VISCOELASTIC ANTIMICROBIAL COMPOSITIONS AND METHODS - Viscoelastic compositions capable of preventing microbial proliferation and capable of capturing microbial membrane and cell wall decomposition products are provided. The compositions comprise thermal reaction products of blends of fatty acids derived and isolated from drying and semi-drying oils such as linseed, safflower, and tung oil, with a polymer component such as for example poly (isobutyl methacrylate). These compositions are capable of capturing microbes and controlling their proliferation at a material on which the compositions are deposited, and further capable of absorption or incorporation of lipopolysaccharide and protein membrane materials and endotoxins. | 10-29-2015 |
Patent application number | Description | Published |
20100249313 | High Styrene SBS Hot Melt Adhesive - Multipurpose hot melt adhesive compositions which are suitable for use as both a construction and elastic attachment adhesive for disposable soft goods, such as disposable diapers, feminine sanitary napkins, surgical drapes, hospital pads, and adult incontinent products. The multipurpose hot melt adhesive compositions have a high level of creep resistance, high bond strength, and relatively low viscosity, and are composed of endblock resin in combination with a linear styrene-butadiene-styrene (SBS) copolymer wherein the copolymer has a styrene content greater than about 35% by weight, and preferably about 38% to about 50% by weight. | 09-30-2010 |
20110021103 | Hot Melt Adhesive Based on Olefin Block Copolymers - A hot melt adhesive composition, comprising a blend of components including about 5% to about 50% by weight of an olefin block copolymer; about 10% to about 70% by weight of a first tackifying resin having a softening point of at least about 95° C.; about 0 to 65% of a second tackifying resin that is different than the first tackifying resin; about 0% to about 60% by weight of a plasticizer; about 0% to about 20% by weight of an aromatic reinforcing resin having a softening point equal to or higher than 115° C.; about 0.1% to about 5% by weight of a stabilizer; and about 1% to about 40% by weight of a secondary polymer that is different from the olefin block copolymer, the first and second tackifying resins and the reinforcing resin, having relatively low crystallinity, which low crystallinity is equal to or less than 250 Joules/gram, wherein the components total 100% by weight of the composition, and the viscosity of the composition is equal to or less than about 20,000 mPa·s at 163° C. Laminates, especially those used in disposable soft goods, and methods of making such laminates using the hot melt adhesive composition are also described. The adhesive composition and/or laminate may be used in making a variety of end products such as a disposable diaper, a sanitary napkin, a bed pad, a bandage, a surgical drape, a tape, a label, a plastic sheet, a nonwoven sheet, a paper sheet, a cardboard, a book, a filter, or a package. | 01-27-2011 |
Patent application number | Description | Published |
20100272640 | Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 10-28-2010 |
20110136148 | Monoclonal Antibodies Against GMF-B Antigens, and Uses Therefor - The disclosure relates to monoclonal antibodies (mAbs) preferentially selective for soluble GMF-B (sGMF-B) antigens or for sGMF-B as well as other forms of GMF-B, hybridoma lines that secrete these antibodies or fragments thereof, and the use of such antibodies and antibody fragments to preferentially detect sGMF-B antigens, including for example those expressed by cancer cells or in patients with cancer or dementia. Other aspects of the present disclosure relate to antibodies that are specific to or demonstrate preferential binding to a soluble or secreted form of GMF-B. Yet other aspects relate to antibodies or antibody fragments that are capable of reducing the activity of GMF-B in at least one form, including a soluble form or a secreted form. The present disclosure further relates to monoclonal, chimeric antibodies and fragments thereof, processes for producing such antibodies and their fragments, and their therapeutic and diagnostic uses, including in the treatment and detection of cancer, e.g., human breast, ovary, head, neck, and brain, and dementia. Methods and kits for the immunodetection and immunotherapy of cells or samples which express sGMF-B antigens, e.g., from patient and non-patient samples, are also disclosed. | 06-09-2011 |
20120301395 | Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 11-29-2012 |
20130089873 | MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 04-11-2013 |
20130243760 | MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 09-19-2013 |
20140030739 | MONOCLONAL ANTIBODIES AGAINST GMF-B ANTIGENS, AND USES THEREFOR - The disclosure relates to anti-glial maturation factor beta (“GMF-B”) monoclonal antibodies (mAbs) and fragments thereof, as well as hybridoma lines that secrete antibodies or fragments. Therapeutic and diagnostic uses of such antibodies, including treatment and detection of cancer and dementia, and methods and kits for detecting cells or samples expressing GMF-B, including soluble GMF-B, are also encompassed. | 01-30-2014 |
20140065064 | MONOCLONAL ANTIBODIES AGAINST ALPHA-ACTININ-4 ANTIGENS, AND USES THEREFOR - Monoclonal antibodies (MoAbs or mAbs) specific for ALPHA-ACTININ-4 antigens, hybridoma lines that secrete these ALPHA-ACTININ-4 mAbs, and the use of such mAbs to detect ALPHA-ACTININ-4 antigens, particularly those expressed by cancer cells are disclosed. Chimeric and humanized antibodies based upon these anti-ALPHA-ACTININ-4 mAbs, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer are also disclosed. Methods and kits for the immunodetection and immunotherapy of cells for samples which express ALPHA-ACTININ-4 antigens are additionally disclosed. | 03-06-2014 |
20140087400 | DIAGNOSIS AND PROGNOSIS OF TRIPLE NEGATIVE BREAST AND OVARIAN CANCER - In one aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of lymph node metastatis. In another aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of an untreated or treated prognosis that is reduced compared to an absence of the expression. | 03-27-2014 |
20140178906 | MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 06-26-2014 |
20140248283 | MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 09-04-2014 |
20140322224 | MONOCLONAL ANTIBODIES AGAINST SEROTRANSFERRIN ANTIGENS, AND USES THEREFOR - The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed. | 10-30-2014 |
Patent application number | Description | Published |
20090075996 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia. | 03-19-2009 |
20090137570 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. | 05-28-2009 |
20090270409 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 10-29-2009 |
20100022515 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia. | 01-28-2010 |
20100120807 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 05-13-2010 |
20110166176 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 07-07-2011 |
20110172244 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, of Formula I: pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 07-14-2011 |
20110224185 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 09-15-2011 |
20120196844 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 08-02-2012 |
20130261108 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS - The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 10-03-2013 |
20130331349 | COMPOSITIONS AND METHODS FOR MODULATING FXR - The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 12-12-2013 |